Jorey Chernett, 10% Owner at Starling Oncology, Inc. (STLN), bought 12,000 shares at $6.54 ($78K) on 2026-08-14, disclosed to the SEC on 2026-08-17.
Jorey Chernett, a 10% shareholder, purchased $78,480 worth of 12,000 shares at $6.54, marking the largest insider purchase in the company's history. This significant buy signals confidence in the stock's value following the recent rebranding and earnings results.
The stock is currently trading near its 52-week low of $6.50, having dropped approximately 15% over the past 12 months despite recent earnings beats. The current price of $6.54 is just 0.6% above this 52-week low, indicating the stock is trading at a deep discount.
1) Q2 Earnings Call Highlights on August 7, 2026, which discussed the rebranding to Starling Oncology and expanded pipeline of value-based oncology contracts. 2) Q2 Earnings on June 30, 2026, where the company reported a revenue surprise of +5.55% and an earnings surprise of -14.29%. 3) The largest insider purchase ever recorded, signaling a potential bottom in the stock price.
The stock has a high short interest of 8.3% of the float, which could lead to increased volatility if the stock fails to rally. Additionally, the company reported a negative earnings surprise of -14.29% in the last quarter, indicating potential profitability concerns.
Nothing distinguishes this filing.
| Filing → |
| STIM | BUY | 2026-07-15 | $62K | — | Filing → |
| TOI | BUY | 2026-07-13 | $88K | — | Filing → |
| TOI | BUY | 2026-06-24 | $90K | — | Filing → |